X Chromosome Disorders is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for X Chromosome Disorders have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in X Chromosome Disorders compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
X Chromosome Disorders overview
X chromosome disorders, also termed X-linked disorders, arise from mutations in genes residing on the X chromosome, a pivotal determinant of an individual’s sex. These conditions impact both males and females, albeit with distinct consequences. In X-linked recessive disorders, such as hemophilia and Duchenne muscular dystrophy, males, possessing only one X chromosome, are more susceptible, while females, often asymptomatic carriers, can transmit the disorder. X-linked dominant disorders, exemplified by Rett syndrome, tend to be more severe in females, lacking the compensatory second X chromosome found in males. Sex chromosome aneuploidies, like Turner syndrome (XO) in females and Klinefelter syndrome (XXY) in males, disrupt development and fertility. Disorders like X-linked agammaglobulinemia may stem from irregularities in the natural process of X chromosome inactivation in females, underscoring the complexity of X chromosome-related genetic conditions.
See Also:
For a complete picture of PTSR and LoA scores for drugs in X Chromosome Disorders, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
